Table 2 MSCs-derived EVs in tumor
From: Emerging applications of extracellular vesicles in tumor therapy
Result | Source | Therapeutic agent | Targeting tumors/cells | Research models | Tumor cell lines | Outcomes | References |
|---|---|---|---|---|---|---|---|
Tumor promotion | BM | – | Gastric Cancer | In vivo/in vitro | SGC-7901 and SW480 | Stimulation of tumor angiogenesis by activation of ERK1/2 and p38 mitogen-activated protein kinase pathway induced by VEGF expression | Zhu et al. (2012) |
MMBM | – | MM | In vivo/in vitro | MM.1S, RPMI.8226, and U266 | Supported tumor progression by transfer of lower amounts of the exosomal tumor suppressor miR-15a | Roccaro et al. (2013) | |
UC | – | Gastric Cancer | In vivo/in vitro | HGC-27, MGC-803, and SGC-7901 | Induced drug resistance in gastric cancer cells by activation of CaM-Ks/Raf/MEK/ERK pathway | Ji et al. (2015) | |
AT | – | Glioblastoma | In vitro | U87MG | Promoted the proliferation of cancer cells | Fattore et al. (2015) | |
Tumor inhibition | BM | Hepatocellular carcinoma, Kaposi's sarcoma and ovarian tumors | In vivo/in vitro | HepG2, Skov-3, and Kaposi’s sarcoma cell lines | Inhibited tumor growth | Bruno et al. (2013) | |
UC Wharton's jelly MSCs | – | Bladder cancer | In vivo/in vitro | T24 | Inhibited tumor growth by down-regulating phosphorylation of Akt protein kinase and up-regulated cleaved cystathionine-3 | Wu et al. (2013) | |
AT | – | Prostate cancer | In vivo/in vitro | PC3M-luc2 | Inhibited tumor growth by shifting miR-145 to reduce Bcl-xL activity and promoted apoptosis via the cystatin-3/7 pathway | Takahara et al. (2016) | |
BM and UC | – | Glioblastoma | In vitro | U87MG | Inhibited tumor cell proliferation and promoted tumor cell apoptosis | Fattore et al. (2015) | |
UC | PTX | Glioblastoma | In vitro | U87MG | Increased cytotoxicity to tumor cells | Fattore et al. (2015) | |
MSCs | PTX | Pancreatic cancer | In vitro | CFPAC-1 | Inhibited tumor cell proliferation | Pascucci et al. (2014) | |
MSCs | Anti-miR-9 | Glioblastoma multiforme | In vitro | U87, T98G, BT145, and BT164 | Reversed expression of multidrug transporter proteins and reversed chemotherapy resistance | Munoz et al. (2013) | |
MSCs | miR146b | Glioma | In vivo/in vitro | Glioma cells | Inhibited glioma xenograft progression in a brain tumor model | Katakowski et al. (2013) | |
MSCs | miR-143 | Osteosarcoma | In vitro | 143B | Inhibited osteosarcoma migration | Shimbo et al. (2014) | |
MSCs | miR122 | Hepatocellular carcinoma | In vivo/in vitro | HepG2 | Increased sensitivity of tumor cells to chemotherapeutic agents and tumor growth | Lou et al. (2015) | |
MSCs | miR-379 | Breast cancer | In vivo/in vitro | T47D and HCC-1954 | Inhibited the progression of breast cancer | O'Brien et al. (2018) | |
MSCs | miR-598 | NSCLC | In vivo/in vitro | H1299, A549, H522, and H460 | Inhibited the promotion of proliferation, migration and invasion of NSCLC cells by THBS2 | Li and Wu (2023) | |
Human foreskin fibroblast-like/MSCs | siRNA for oncogenic Kras | Pancreatic Cancer | In vivo | Capan-1, MIA PaCa-2, BxPC-3, and T3M4 | inhibited cancer progression and improved overall survival | Kamerkar et al. (2017) | |
MSCs | antagomiR-222/22 | Breast Cancer | In vivo/in vitro | MDA-MB-231 and T47D | Lead breast cancer dormant and improved chemotherapy sensitivity and survival | Bliss et al. (2016) |